Alexis Chettiar1, Maria Montez-Rath2, Sai Liu2, Yoshio N Hall3, Ann M O'Hare3,4, Manjula Kurella Tamura5,6. 1. Program of Health Policy Nursing, University of California San Francisco, San Francisco, California. 2. Division of Nephrology, Stanford University School of Medicine, Palo Alto, California. 3. Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington. 4. Department of Hospital and Specialty Medicine, Veteran Affairs Puget Sound Health Care System, Seattle, Washington; and. 5. Division of Nephrology, Stanford University School of Medicine, Palo Alto, California; mktamura@stanford.edu. 6. Geriatric Research and Education Clinical Center, Palo Alto Veteran Affairs Health Care System, Palo Alto, California.
Abstract
BACKGROUND AND OBJECTIVES: Palliative care may improve quality of life and reduce the cost of care for patients with chronic illness, but utilization and cost implications of palliative care in ESKD have not been evaluated. We sought to determine the association of inpatient palliative care with health care utilization and postdischarge outcomes in ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In analyses stratified by whether patients died during the index hospitalization, we identified Medicare beneficiaries with ESKD who received inpatient palliative care, ascertained by provider specialty codes, between 2012 and 2013. These patients were matched to hospitalized patients who received usual care using propensity scores. Primary outcomes were length of stay and hospitalization costs. Secondary outcomes were 30-day readmission and hospice enrollment. RESULTS: Inpatient palliative care occurred in <1% of hospitalizations lasting >2 days. Among the decedent cohort (n=1308), inpatient palliative care was associated with a 21% shorter length of stay (-4.2 days; 95% confidence interval, -5.6 to -2.9 days) and 14% lower hospitalization costs (-$10,698; 95% confidence interval, -$17,553 to -$3843) compared with usual care. Among the nondecedent cohort (n=5024), inpatient palliative care was associated with no difference in length of stay (0.4 days; 95% confidence interval, -0.3 to 1.0 days) and 11% higher hospitalization costs ($4275; 95% confidence interval, $1984 to $6567) compared with usual care. In the 30-day postdischarge period, patients who received inpatient palliative care had higher likelihood of hospice enrollment (hazard ratio, 8.3; 95% confidence interval, 6.6 to 10.5) and lower likelihood of rehospitalization (hazard ratio, 0.8; 95% confidence interval, 0.7 to 0.9). CONCLUSIONS: Among patients with ESKD who died in the hospital, inpatient palliative care was associated with shorter hospitalizations and lower costs. Among those who survived to discharge, inpatient palliative care was associated with no difference in length of stay and higher hospitalization costs but markedly higher hospice use and fewer readmissions after discharge.
BACKGROUND AND OBJECTIVES: Palliative care may improve quality of life and reduce the cost of care for patients with chronic illness, but utilization and cost implications of palliative care in ESKD have not been evaluated. We sought to determine the association of inpatient palliative care with health care utilization and postdischarge outcomes in ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In analyses stratified by whether patients died during the index hospitalization, we identified Medicare beneficiaries with ESKD who received inpatient palliative care, ascertained by provider specialty codes, between 2012 and 2013. These patients were matched to hospitalized patients who received usual care using propensity scores. Primary outcomes were length of stay and hospitalization costs. Secondary outcomes were 30-day readmission and hospice enrollment. RESULTS: Inpatient palliative care occurred in <1% of hospitalizations lasting >2 days. Among the decedent cohort (n=1308), inpatient palliative care was associated with a 21% shorter length of stay (-4.2 days; 95% confidence interval, -5.6 to -2.9 days) and 14% lower hospitalization costs (-$10,698; 95% confidence interval, -$17,553 to -$3843) compared with usual care. Among the nondecedent cohort (n=5024), inpatient palliative care was associated with no difference in length of stay (0.4 days; 95% confidence interval, -0.3 to 1.0 days) and 11% higher hospitalization costs ($4275; 95% confidence interval, $1984 to $6567) compared with usual care. In the 30-day postdischarge period, patients who received inpatient palliative care had higher likelihood of hospice enrollment (hazard ratio, 8.3; 95% confidence interval, 6.6 to 10.5) and lower likelihood of rehospitalization (hazard ratio, 0.8; 95% confidence interval, 0.7 to 0.9). CONCLUSIONS: Among patients with ESKD who died in the hospital, inpatient palliative care was associated with shorter hospitalizations and lower costs. Among those who survived to discharge, inpatient palliative care was associated with no difference in length of stay and higher hospitalization costs but markedly higher hospice use and fewer readmissions after discharge.
Authors: Albert H A Mazairac; G Ardine de Wit; E Lars Penne; Neelke C van der Weerd; Boudewijn de Jong; Muriel P C Grooteman; Marinus A van den Dorpel; Erik Buskens; Friedo W Dekker; Menso J Nubé; Piet M Ter Wee; Els W Boeschoten; Michiel L Bots; Peter J Blankestijn Journal: Nephrol Dial Transplant Date: 2010-11-04 Impact factor: 5.992
Authors: Sara N Davison; Adeera Levin; Alvin H Moss; Vivekanand Jha; Edwina A Brown; Frank Brennan; Fliss E M Murtagh; Saraladevi Naicker; Michael J Germain; Donal J O'Donoghue; Rachael L Morton; Gregorio T Obrador Journal: Kidney Int Date: 2015-04-29 Impact factor: 10.612
Authors: Melissa W Wachterman; Corey Pilver; Dawn Smith; Mary Ersek; Stuart R Lipsitz; Nancy L Keating Journal: JAMA Intern Med Date: 2016-08-01 Impact factor: 21.873
Authors: Glenn Gade; Ingrid Venohr; Douglas Conner; Kathleen McGrady; Jeffrey Beane; Robert H Richardson; Marilyn P Williams; Marcia Liberson; Mark Blum; Richard Della Penna Journal: J Palliat Med Date: 2008-03 Impact factor: 2.947
Authors: Anne M Murray; Cheryl Arko; Shu-Cheng Chen; David T Gilbertson; Alvin H Moss Journal: Clin J Am Soc Nephrol Date: 2006-09-06 Impact factor: 8.237
Authors: R W Evans; D L Manninen; L P Garrison; L G Hart; C R Blagg; R A Gutman; A R Hull; E G Lowrie Journal: N Engl J Med Date: 1985-02-28 Impact factor: 91.245
Authors: Kabir O Olaniran; Shananssa G Percy; Sophia Zhao; Chantal Blais; Vicki Jackson; Mihir M Kamdar; Jeremy Goverman; Daniela Kroshinsky; Jennifer S Temel; Sagar U Nigwekar; Nwamaka D Eneanya Journal: J Pain Symptom Manage Date: 2018-11-03 Impact factor: 3.612
Authors: Jessica Ma; Stephen Chi; Benjamin Buettner; Katherine Pollard; Monica Muir; Charu Kolekar; Noor Al-Hammadi; Ling Chen; Marin Kollef; Maria Dans Journal: Crit Care Med Date: 2019-12 Impact factor: 7.598
Authors: Adeyinka Charles Adejumo; Donghee Kim; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; George Cholankeril; Robert J Wong; Paul Y Kwo; Aijaz Ahmed Journal: J Palliat Med Date: 2019-08-09 Impact factor: 2.947
Authors: Yumeng Wen; Changchuan Jiang; Holly M Koncicki; Carol R Horowitz; Richard S Cooper; Aparna Saha; Steven G Coca; Girish N Nadkarni; Lili Chan Journal: J Am Soc Nephrol Date: 2019-08-06 Impact factor: 10.121